Internet Drug
Pharmaceutical News & Information; Updated Daily

Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
ΏYour Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

6/23 Senate Version of AHCA Slows Medicaid Cuts
Senate GOP's Health Bill Sends Hospitals, Pharma Stocks Higher .... A draft version of the Senate bill indicates that spending in Medicaid, one of the biggest sources of government health care spending, would be lowered more slowly than under the House version .... Bloomberg

6/23 Pharma Execs Weigh in on FDA, Industry Issues
The Endpoints 100 CEO Survey: Execs offer a big thumbs up for Gottlieb and some suggestions for making the FDA a better agency .... The FDA is understaffed in key areas, and most want to see generics pushed through faster. Biotech execs want more regulators, and they want better staff with more expertise in their field. .... Endpoints

6/23 FDA to Take a Look at Oncology Marketing — Do Patients and HCPs Understand the "Fine Print"
The FDA attempts to understand how disclosures affect drug ads .... One of the two proposed studies will examine the effects of disclosures in oncology promotion. The other will examine disclosures in professional and consumer drug promotion, regardless the type of drug advertised .... MM&M

6/23 Canakinumab Cuts Cardiovascular Risk for Heart Attack Survivors
Novartis heart drug success opens up new care option .... Because canakinumab works differently than existing drugs given after a heart attack, such as cholesterol-lowering statins or blood-thinners, it could be given on top of standard medicines .... Reuters

See also:
6/23 Drug Used for Juvenile Arthritis Also Reduces Heart Risk for Adults; Success for Cardiac Indication Requires Much Lower Pricing
Novartis' CANTOS Heart Trial Results Could Lead To Drastic Drop In Arthritis Drug Price .... Novartis would be hard pressed to make the case that Ilaris (canakinumab) for juvenile idiopathic arthritis should be priced at $200,000/patient/year, whereas using the same drug (undoubtedly with a different tradename) for CV disease can be priced at $9,000/patient/year .... Forbes/John LaMattina

6/23 Shkreli Fraud Trial Begins Next Week
Martin Shkreli, 'Pharma Bro,' Prepares for Trial: 'I'm So Innocent' .... Novartis would be hard pressed to make the case that Ilaris (canakinumab) for juvenile idiopathic arthritis should be priced at $200,000/patient/year, whereas using the same drug (undoubtedly with a different tradename) for CV disease can be priced at $9,000/patient/year .... NY Times

6/23 Draft Senate Bill Cuts Recovery Treatment Programs from $45 Billion to $2 Billion
The New Health Care Bill Would Mean Big Cuts For Opioid Addiction Treatment .... Medicaid now covers 3 in 10 people with an opioid addiction and faces a proposed $830 billion cut .... Buzzfeed

6/23 Mylan's Medicaid Deals for EpiPens
Mylan offered EpiPen discounts to states in exchange for privileged status, documents show .... Mylan offered rebates to at least six state Medicaid programs on the condition that the states would make it harder for Medicaid patients to obtain products that compete with its EpiPen auto-injector .... Stat

6/23 Opdivo First-Line Lung Cancer Trial Failure Based on Flaky Test
Was Bristol-Myers Squibb's assay to blame for Opdivo's first-line lung flop? .... Full results from Bristol-Myers Squibb's infamous Opdivo monotherapy trial in first-line lung cancer are finally out—alongside a theory about why that trial came up short .... Fierce Pharma

6/23 Congress Looks into the Insulin Ripoff
Lawmakers make bipartisan push to understand the soaring price of a lifesaving drug .... A form of insulin that carried a list price of $17 a vial in 1997 cost $138 in 2016. Another form that launched two decades ago at $21 a vial rose to $255 .... Washington Post

6/23 New Understanding of Parkinson's Disease Mechanism
Parkinson's is partly an autoimmune disease, study finds .... The new study found that T cells can be tricked into thinking dopamine neurons are foreign by the buildup of damaged alpha-synuclein proteins, a key feature of Parkinson's diseas .... Medical Xpress

6/23 Internet Drug News Fast Takes:
Epizyme's tazemetostat an Orphan Drug for soft tissue sarcoma
Seeking Alpha
Nevada Transparency Bill Targets Diabetes Drugs and Payments to Health Care Providers
FDA Law Blog
Proton pump inhibitors do not contribute to dementia or Alzheimer's disease
American Geriatrics Society
Popular prostate drug linked to serious side effects
Boston University Medical Center
Research suggests sexual appeals in ads don't sell brands, products
University of Illinois at Urbana-Champaign

6/22 CRO Parexel Goes Private with Pamplona Capital
Wobbly Parexel International snapped up for $5B in latest CRO buyout .... The big CRO shakeup continues this morning with news of Pamplona Capital's $5 billion acquisition of Parexel International, one of the biggest players in the business .... Endpoints News

6/22 Handy Table of Blockbuster Drugs on the Way
Top 20 blockbuster drugs in the late-stage pipeline – EvaluatePharma .... AbbVie has 4 drugs in late-stage development that fall in the top 20, more than any other company on the list .... Endpoints

6/22 Gottlieb Promises to Break Up Agency Logjams, Speed Generic Reviews
FDA Commissioner Vows to Eliminate Backlog of Orphan Drug Designation Requests .... Gottlieb promised to "completely eliminate" the orphan drug designation requests backlog within 90 days and will strive to address all future requests within 90 days .... Regulatory Focus

6/22 Inside the Express Scripts Black Box
A Wall Street investor call revealed part of the secret of why drugs are so expensive .... While Express Scripts' primary function is supposed to be keeping costs down for clients, in this case it also makes money off of every way Acthar -- which has seen its price jump 3,000% in a decade -- gets to a patient .... Business Insider

6/22 Inside the AmerisourceBergen Black Box
Why did these generic drugs' prices jump as much as 85%? .... Drug manufacturers and pharmaceutical middlemen tend to point fingers at each other .... Marketwatch

6/22 When Ads to Doctors, and Direct-to-Consumer Ads Fall Short, Allergan Finds Migraineurs on Facebook
Allergan reaches the masses via unbranded Botox Facebook page .... "There are a lot of people in our target that we can't get to via just traditional DTC or direct-to-physician-type marketing," admitted Marc Forth, Allergan's SVP of sales and marketing in neurosciences and urology. "The reach of Facebook across millions and millions of consumers is undeniable." .... MM&M

6/22 Mylan Thrives on Coal Tax Credits
Drugmaker Mylan gets boost from unlikely source: coal .... Since 2011, Mylan has bought 99 percent stakes in five companies across the U.S. that own plants which process coal to reduce smog-causing emissions. It then sells the coal at a loss to power plants to generate the real benefit for the drug company: credits that allow Mylan to lower its own tax bill .... Reuters

6/22 McKinsey, the "Consultants that Run the World" Recommend a Strategy for Emerging Markets
What's next for pharma in emerging markets? .... Succeeding in emerging markets has been a challenging undertaking for multinational pharma companies, but those that adapt their end-to-end model for emerging markets could well thrive .... McKinsey

6/22 Pharma Pivots Alzheimer's Development Away from Amyloid
Alzheimer's Drug Pipeline Analysis: Have We Hit Peak Amyloid? .... Of the 105 drugs the authors found in clinical studies as of this January, 41 are designed to attack amyloid in one form or another. More than half of the drugs in Phase 3 are anti-amyloid. But the percentages in Phase 2 are much lower—14 of 52 drugs .... xconomy

6/22 Programmatic Targeted Ads Lifted Sales $23 Million; $4.53 Incremental Retail Return on Ad Spend
How Zicam made the most of TV's cold season .... The solution for a greater return on Zicam television ads by Simulmedia was two fold: custom targeting and data-optimized delivery. Simulmedia Created a custom target based on age, gender, household income, and multiple MRI attributes to better hone in on the target audience. .... MM&M

6/22 Internet Drug News Fast Takes:
Mark Bertolini: We're moving Aetna, but not telling anybody where yet
CNBC (autoplay video)
Who Needs A Hospital, When This Self-Driving Doctor Comes To You?
Co. Design
Amgen asks FDA to consider new uses for Xgeva
Pacific Coast Business Times
GSK wins $235 million from Teva in Coreg patent trial
The high price of anticancer drugs: origins, implications, barriers, solutions
Nature Review/Clinical Oncology

6/21 Trump Drug Policy: Roll Back Regulations
Draft Order on Drug Prices Proposes Easing Regulations .... The draft... is light on specifics but clear on philosophy: Easing regulatory hurdles for the drug industry is the best way to get prices down .... NY Times

6/21 Who's Making All the Money? Drug Channels Looks at the Numbers
Profits in the 2017 Fortune 500: Manufacturers vs. Wholesalers, PBMs, and Pharmacies .... Using the Fortune data, I explore the profitability and shareholder returns of the largest public drug wholesalers, chain pharmacies, and pharmacy benefit managers (PBMs). I compare these companies with the Fortune 500's ten pharmaceutical manufacturers and a separate survey of independent pharmacies .... Drug Channels/Adam Fein

6/21 FDA Push: 'Tumor-Agnostic' Therapies That Treat a Mutation, Not A Particular Tumor Site
FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes .... In a long-awaited move, U.S. drug regulators will simplify the approval of treatments targeting specific gene mutations that can spur tumors in a variety of organs .... Bloomberg

6/21 Drug Sales Expected to Grow 6.5% Per Year Through 2022
For the first time, analyst group lowers 2022 sales forecast as pricing backlash takes a toll .... Evaluate has reduced its 2022 projection by $60 billion, to $1.06 trillion. That is down from the $1.12 trillion in 2022 sales it had projected last year .... Fierce Pharma
See also: Worldwide drug sale forecasts fall as pricing pressures mount [Reuters]

6/21 Victoza Lowers Cardio Risks, Panel Says
FDA panel supports cardiovascular indication for Novo's diabetes drug Victoza .... By a 17-2 vote, the panel concluded that an outcomes trial dubbed Leader provides significant evidence demonstrating the CV benefit for Novo's blockbuster's GLP-1 diabetes medication .... Fierce Pharma

6/21 Experts: 'Look at Cardiovascular Disease, Not Just Glucose Control for Diabetics'
Researchers call for paradigm shift in type 2 diabetes treatment .... Results from four recent randomized clinical trials suggest that using medications that offer glucose control while reducing the risk for cardiovascular disease could improve patient outcomes .... Case Western Reserve University

6/21 How to Market a Drug that Costs 80x What It's Worth: The Case of Vimovo
How Two Common Medications Became One $455 Million Specialty Pill .... To get Vimovo covered, Horizon made deals with insurance payers and pharmacy benefit managers -- the intermediaries who help determine which drugs get reimbursed. The contracts generally included special rebates and even administrative fees for these intermediaries, the Horizon reports said, so the drug maker got paid much less than the sticker price, though it wouldn't say how much. But the company's net sales show the deals worked .... The Atlantic

6/21 Trump's Executive Order on Drug Prices Waiting in Line Behind Health Reform
Trump drug pricing order may be weeks away .... The White House may wait until after the Senate calls a vote on health reform before issuing an executive order on drug pricing .... CNBC

6/21 Mydayis Works for 16 Hours, Topping Adderall XR's 12
Shire's long-acting ADHD drug wins U.S. approval .... Shire's SHP465 drug, known as Mydayis, contains the same active ingredient as the company's widely used ADHD treatment Adderall XR but is formulated to last up to 16 hours .... Reuters

6/21 Fewer Injections for Macular Degeneration With Brolucizumab
Novartis Eye Drug Works With Fewer Injections Than Rival .... Head-to-head late-stage trials showed RTH258, which goes by the generic name brolucizumab, worked as well as Regeneron's Eylea, with just over half the patients needing doses every 12 weeks, rather than every eight weeks for Eylea .... Reuters via NY Times

6/21 Fraudulent Sober Homes
Haven for Recovering Addicts Now Profits From Their Relapses .... Delray Beach, Fla., was once a godsend for substance abusers. But now, a sprawl of fraudulent outpatient centers capitalizes on addicts' thwarted recoveries .... NY Times

6/21 Internet Drug News Fast Takes:
Supreme Court ruling threatens massive talc litigation against J&J
Thousands of genes influence most diseases, Stanford researchers report
Stanford University Medical Center
A frantic scramble before possible healthcare vote next week
The Hill
Some Light Shopping With Your Drug Infusion?
(Medical providers taking space in shopping malls)
WSJ $$
Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
Open Forum Infectious Diseases
Drugmakers must take the lead on opioid epidemic comms, say experts

June 20th Fast Takes
Slammed by more deaths, Seattle Genetics scraps a PhIII study and pulls back (again) on vadastuximab
Endpoints News
Data Points: Physician shortage projected to grow
Modern Healthcare
GSK's new pharma head to join in September after AstraZeneca tussle
Does it pay to pay HIV patients to take their meds?

6/20 Supremes Rebuff Plavix Ambulance Chasers
Thou shalt not cherry pick venues
Supreme Court limits jurisdictional reach of state courts in Plavix class action … weren't prescribed Plavix in the state, didn't buy or take the drug there, and weren't injured by the drug there  …  incorporated in Delaware and headquartered in New York … [American Bar Association]

FDA Green Lights New Fluoroquinolone For Serious Skin Infections
- Kills MRSA bugs, price unknown
FDA approves new antibiotic to treat serious skin infections
… infusion or in oral form. … Baxdela, or delafloxacin, is designed to treat skin and skin structure infections caused by a range of bacteria, including methicillin-resistant staphylococcus aureus … [Reuters]

6/20 Pharma Leaner & Meaner? Not Quite
- Only GSK, JNJ get it right
The myth of "leaner and meaner" pharma … investors should be skeptical of claims that layoffs and other "strategic initiatives" are boosting pharma's net return on talent. … outsourcing has continued to grow in personnel-intensive areas like clinical development … [Endpoints News]

Roche's Large Molecule Patent Cliff
3 Roche biotech blockbusters face biosim competition
Novartis throws down gauntlet to Roche with Rituxan copy … first wave of copycats now hitting the market, including Novartis's Rixathon and Celltrion's Truxima … three established blockbusters Rituxan, Herceptin and Avastin, all face increasing biosimilar competition by the end of the … [Reuters]
Novartis wins another biosimilar round with an OK for its Rituxan copycat In Europe
… [Endpoints News]

6/20 Bicarb Shortage Intensifies
Aussie imports 11x more expensive: $450 for a bag that costs $40 To make
Hospira recalls sodium bicarbonate vials as the drug shortage gets worse … 150 milliequivalents of sodium bicarbonate traditionally cost around $40 to make. The imported variety has ballooned to nearly $450 … [ModernHealthcare]
Pfizer recalls injectables made at Rocky Mount over potential contamination risk … Pfizer has recalled four injectables - including the already scarce heart surgery drug Sodium Bicarbonate - made at Hospira's facility in Rocky Mount, North Carolina after identifying a potential contamination risk …[In Pharma Technologist]

Mylan:  Investors Mad As Hell;  CEO, Board Hanging By A Thread
Investors are being told to go scorched earth on the company that makes EpiPen … urging shareholders vote against 10 of  Mylan's 11 current board members, including CEO Heather Bresch … EpiPen price-hiking debacle spawned a global backlash that hurt both the company's reputation and share price …[Yahoo Business Insider]

6/20 EpiPen Knockoff Price Anyone's Guess
Adamis has not set US price for newly approved rival to Mylan's $600 EpiPen … reports in the US suggest Symjepi will cost between $225 and $425 … Adamis does intend to position this product as the low cost alternative to the other offerings in this market … [In-Pharma Technologist]

When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War
- 88% of PCSK9 prescripotions rejected by insurance companies
When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War … hasn't been approved despite her and her doctor's numerous applications and efforts … in 2016, 88.4% of patients with a commercial insurance plan were rejected  when trying … [WSJ]

Data Miner Uses Walgreens Data To Recruit Guinea Pigs
- Acurian knows a lot about you
How a Company You've Never Heard of Sends You Letters about Your Medical Condition … Walgreens, which uses a privacy exemption for research, to send recruitment letters to its pharmacy customers on Acurian's behalf, based on the medications they're using … services of a startup that advertises its ability to unmask anonymous website visitors … [Gizmodo]

June 19th Fast Takes:
Could Legalized Marijuana Be Making Big Pharma Nervous?
Amazon's Whole Foods deal pummels pharmaceutical stocks
Market Watch
Semen Allergies Are A Very Real Thing That Make Sex A Bit More Complicated\
Merck boss hits back at drug pricing criticism
Telegraph UK

Trump Exec Order On Drug Prices Unlikely To  Upset Industry
Trump's drug price 'remedy' expected to be industry friendly … administration proposals under discussion may help -- rather than harm the drug industry. … such as announcing the FDA will speed generic drug approvals -- a move that would spur competition among these cheaper copycats of branded medicines …[Politico]
Trump plan on drug prices likely to be friendly to drug industry … executive order was originally expected to have a negative impact on the pharmaceutical industry, but the policies now under consideration would not do so … [The Hill]

Heard On Cafι Pharma: Janssen Lays Of Invokana Reps:
Janssen amputates Invokana selling contract rep sales force … [Cafι Pharma Message Board]

True Story: My Kybella Experience: Injection Melts Away Double Chin
- Today chins, tomorrow granny arms? Belly?
The Injection That Melts a Double Chin … I was about to have vials of synthetic stomach acid shot into my double chin, erasing it, I hoped, forever … The dissolved fat is now cellular debris, and gets cleared into the lymphatic and circulatory systems by specialized immunologic cells. This happens gradually over the span of several weeks … [The Atlantic]

Mylan's Generic Copaxone Faces More Delays
- Analyst claims no launch until  2018
Mylan's Copaxone copy could face another hold-up with FDA info request … "Our base case remains no Copaxone generic in 2017 … CEO Heather Bresch said Wednesday that the company had received an "information request" from the FDA regarding its 20 mg Copaxone copy. …[Fierce Pharma]

Cancer Patient Sues Celgene Claiming Revlimid Price Gouging
Claims Celgene scheme unfairly prevented generic
Cancer Patient Sues Big Pharma for Illegal Price Gouging … Celgene's behavior wasn't about safety, it was about protecting its monopoly, propping up its stock, and pocketing billions in profit … price of Revlimid increased 34 percent and Mitchell's co-payments jumped by 600 percent … [Patients for Affordable Drugs]
Cancer patient sues Celgene for thwarting generic versions of its pricey meds … [Pharmalot]

Inhaled Insulin:  Will It Ever Be A Big Seller?
- Will reality TV and TV commercials be enough to drive sales?
MannKind's Afrezza needs a big turn. Can reality TV and a new commercial get it done? … Also part of the push are targeted advertising, such as a USA Today direct mail campaign; sporting events, digital and social efforts, and more recently, point-of-care marketing in physicians' offices through a deal with Outcome Health … [Fierce Pharma]

5 Things You Didn't Know About Eli Lilly
- How they make their money, how they feel about mergers, why are they stuck in neutral
5 Things You Didn't Know About Eli Lilly … one of seven drugmakers that relied on price hikes for 100% of its earnings growth last year. … sale of medicines to veterinarians made up about 15% of total revenue. … disruption that megamergers cause would outweigh any cost-saving benefits … [ Motley Fool]

6/16 Nevada Law Will 'Open Up the Books' for Diabetes Meds; Reps Must Register with the State
Nevada just passed one of the strictest drug pricing transparency laws in the country .... The law requires diabetes drugmakers that have raised drugs' list prices by a certain amount to disclose information about the costs of making and marketing the drugs, along with what rebates they provide.... Pharmacy benefit managers will also have to disclose what rebates they negotiate with diabetes drugmakers .... Business Insider

6/16 CVS Proposes a Plan Where Consumers Get Rebates at the Pharmacy Counter (Rather the Payments Going Back to the Health Plan). Adam Fein Breaks Down How this Might Work
Will CVS Health's Point-of-Sale Rebates Deflate the Gross-to-Net Bubble — and Disrupt the PBM Business? .... CVS Health's white paper implies that a switch to POS rebates will require only a few actuarial math tweaks. But the reality is more complex. A major barrier is health plans and employers, both of which have baked ever-growing rebate dollars into their healthcare economics .... Drug Channels

6/16 Symjepi Approved; Competition for EpiPen
Adamis wins U.S. approval to sell EpiPen rival .... The company is looking for a marketing partner and would set a price for the product before its launch sometime in the second half of this year .... Reuters

6/16 Opioids the 'New Tobacco': State AGs Teaming Up to File Suits
Drug Makers Being Probed by States Over Opioid Marketing .... The most "sinister" potential wrongdoing would involve companies being fully aware of the addictive nature of the drugs and banking on it to increase profit -- a worst-case scenario similar to what happened with the tobacco industry (Jon Barooshian, a former state prosecutor in Massachusetts) .... Bloomberg

6/16 NASH Gold Rush May Stumble Over OBA Pricing; Currently $70,000/Year
Despite Clinical Promise, Obeticholic Acid May Be Too Expensive for Treating NASH .... "In the best possible case, the cost for each additional quality life-year would be $2.5 million, which is not close to the common threshold for acceptable cost-efficacy," (Jagpreet Chhatwal, PhD, Massachusetts General Hospital) .... Gastroenterology and Endoscopy News

6/16 No Progress for Mylan's Copaxone Generics
Mylan in FDA Limbo On Generic Multiple Sclerosis Drug .... Mylan has received an "information request" from the FDA into its 20-milligram version of the multiple sclerosis drug. But Mylan didn't offer an update regarding its 40-milligram version .... Investors' Business Daily

6/16 Not Enough Money or Patients to Find Targeted Cancer Drugs
Cancer's Big Infrastructure Problem .... But given the rarity of these genetic mutations (to give another example, Ros1, another lung cancer mutation given by targeted cancer drugs, is found in only 2% of non-small cell lung cancer patients), how do you go about finding enough patients for a clinical trial? .... Forbes/Matthew Herper

6/16 Gottlieb Streamlines Review of Digital Products; Creates Lower-Risk/Higher-Risk Pathways
FDA Pilot to Sign Off on Low-Risk Digital Health Products Without Premarket Review .... FDA Commissioner Scott Gottlieb has announced an upcoming pilot program that would create a third-party certification program under which lower-risk digital health products could be marketed without FDA premarket review and higher-risk products could be marketed with a streamlined FDA review .... Regulatory Focus

6/16 AMA Says Include List Prices in All DTC Ads
AMA calls for more transparent prescription costs .... The AMA urged federal agencies to require that manufacturers list the suggested retail prices of medications on direct-to-consumer ads. The AMA referenced a study that indicated a 34.2% price increase for prescription drugs that were advertised to consumers directly, while there was only a 5.1% increase in the price of other pharmaceuticals .... Healio

6/16 Positive Cosentyx Extension Trial Results
Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis .... By the two-year point, 28% of psoriatic arthritis patients treated with Cosentyx — almost all of whom had reported moderate-to-extreme pain or discomfort before starting on the drug — felt no pain or discomfort at all .... Fierce Pharma

6/16 Internet Drug News Fast Takes:
*** Recommended ***  As America's Opioid Crisis Spirals, Giant Drug Distributor McKesson Is Feeling the Pain
Fortune (autoplay video)
FDA updates on Pfizer drug shortages
Google's Owner Is Getting Into Drugs
Bloomberg Gadfly
Mistaken antibodies may have led breast cancer research down a 20-year dead end
Medical Xpress
Early stress confers lifelong vulnerability causing alterations in a specific brain region
Medical Xpress
Craig Venter's 'Digital-to-Biological Converter' Is Real

6/15 How Cleveland Clinic Saved $90 Million in Drugs Costs: Their Strategies and Tips
Hospitals Rein in Drug Costs for Inpatients .... Cleveland Clinic has been able to rein in drug spending without harming quality, saving $90 million between 2010 and 2016.... About 45 percent of the $90 million was achieved on the inpatient side by reinforcing traditional pharmacy management approaches, such as inventory control, formulary management, procurement and drug-utilization review .... Hospitals and Health Networks

6/15 Profile of ex-NIMH Head Tom Insel, Who's Now Working on Smartphone Apps to Support and Monitor Those Struggling with Mental Illness
The Smartphone Psychiatrist .... Frustrated by the failures in his field, Tom Insel, a former director of the National Institute of Mental Health, is now trying to reduce the world's anguish through the devices in people's pockets .... The Atlantic

6/15 "Fast-tracked" Pimodivir May Join Standard Flu Armamentarium
Johnson & Johnson's flu drug succeeds in mid-stage trial .... Treatment with pimodivir alone resulted in a statistically significant reduction in viral load in patients over seven days from the start of dosing, when compared with a placebo.... Adding pimodivir to oseltamivir also resulted in a significantly lower viral load compared to those who received pimodivir alone .... Reuters

6/15 SNY to Spend $673 Million on Biologics in Next 2-3 Years
Sanofi to invest further in biologics .... "In 2012, 43 percent of our pipeline was made of biologics. The figure stood at around 60 percent in 2016 and in 2020, it will increase even more" (Philippe Luscan, executive vice president) .... Reuters

6/15 Rebates Grew 9% in 2016
New Data Show the Gross-to-Net Rebate Bubble Growing Even Bigger .... The total value of pharmaceutical manufacturers' off-invoice discounts, rebates, and other price concessions has more than doubled over the past five years, from $59 billion 2012 to an astonishing $127 billion in 2016 .... Drug Channels/Adam Fein

6/15 Insulin Deal Blows Up
Blink Health terminates deal with Express Scripts .... The discount program for insulin between Eli Lilly, Express Scripts and Blink Health, which was announced in December, was designed for patients who were paying for insulin largely out-of-pocket and offered discounts of up to 40 percent off list prices .... St. Louis Business Journal

6/15 What's Coming on Drug Pricing
Senate, White House Working On Drug Pricing .... The White House is drafting an Executive Order on drug pricing. The order will instruct executive agencies to use value-based contracts for drug purchases, and to pursue trade policies that enhance the intellectual property rights of American pharmaceutical companies .... BioCentury

6/15 Give Yourself a Shot and Your Doctor Knows
Bayer aims to drive patient-HCP dialogue with data-sharing app for MS .... Patients can connect the electronic autoinjector to the smartphone app via Bluetooth and then that injection data can be shared with a physician or nurse. The healthcare professional can view the data through the Betaconnect Navigator platform to see data about their patient's injection history .... MM&M

6/15 After Two FDA Holds, Tanezumab is Now on the Fast Track
Tanezumab Gets Fast Track Designation From FDA for Chronic Pain Conditions .... Tanezumab (RN624) is an investigational humanized monoclonal antibody that selectively targets, binds to, and inhibits nerve growth factor (NGF) .... Practical Pain Management

6/15 Neulasta Copy: Do Not Pass Go, Do Not Collect $$
FDA rejects Coherus' biosimilar for Amgen's Neulasta .... The FDA requested Coherus for a re-analysis of certain data and asked the drug developer for more manufacturing information .... Reuters

6/15 Internet Drug News Fast Takes:
Request for Nominations for Individuals and Consumer Organizations for Advisory Committees
The Fertility Doctor Trying to Commercialize Three-Parent Babies
Technology Review
Drug distributors, PBMs seek to block Cherokee Nation opioid suit
Modern Healthcare
A surprising new link between inflammation and mental illness
Medical Xpress
'How Long Have I Got, Doc?' Why Many Cancer Patients Don't Have Answers
Kaiser Health News

6/14 Keytruda for Multiple Myeloma Trials Discontinue New Subjects
Merck Pauses Enrolling Blood Cancer Studies, Cites Deaths .... Merck is pausing enrollment of two studies of its Keytruda cancer immunotherapy treatment in patients with a form of blood cancer, following reports of deaths among those taking the drug .... Bloomberg

6/14 How Patient Assistance Charities Work
U.S. Probe Sheds Light on Charities' Role in Boosting Drug Sales .... Drugmaker donations to charities assisting prostate-cancer patients have dropped in wake of federal investigation, leading drug sales to fall .... WSJ $$

6/14 ICER and Its Critics
The New War On (Overpriced) Drugs .... For the most part, Pearson says, Americans have no idea what they should be paying for medication. We don't how much it costs to actually develop a drug; the FDA doesn't require comparative effectiveness studies, so we don't know if new drugs work better than existing competitors; and we have little information about how much other consumers are paying for the same products .... Wired

6/14 Think Tank Says Keep Close Eye on Labor Costs; Predicts HDHPs on the Way Out
Healthcare costs at 'new normal' but still outpacing wages, inflation .... Medical costs have seemingly settled into a "new normal" where increases have hung behind 6-7% for four years.... PricewaterhouseCoopers' Health Research Institute expects a 6.5% medical cost growth rate increase for 2018. .... Healthcare Dive

6/14 Deep Dive into Generics Data from AAM: 89% of Prescriptions Dispensed But Only 26% of Total Medicine Spending
Generic drugs see low abandonment rate .... Overall, 20.5% of branded scripts were never filled, compared with 7.7% of generics. In addition, branded products account for 20% of approved claims but represent 40% of all abandoned claims for new patients. .... Chain Drug Review

6/14 More Vivitrol Coverage
Seizing on Opioid Crisis, a Drug Maker Lobbies Hard for Its Product .... Five years ago, Vivitrol was a treatment for opioid addiction that was struggling to find a market. Now, its sales and profile are rising fast, thanks to its manufacturers' shrewd use of political connections, and despite scant science to prove the drug's efficacy .... NY Times

6/14 Facebook Invites In Pharma for Meetings and Pitches
Like? Pharma and OTC brands get the Facebook treatment at first of many confabs .... Drugmakers, both pharma and OTC, made up up the guest list at the confab, which focused on mobile marketing. But along with the day-long slate of insights and best practices, the event also aimed to reassure pharma about the safety and effectiveness on social media .... Fierce Pharma

6/14 ER Amantadine Helpful for Parkinson's Movements, 'Off' Time; But Visual Hallucinations for 25%
Drug reduces dyskinesia, 'off' times in Parkinson's patients .... When 58 patients were given placebo for 12 weeks, they improved by 8.0 points on a test designed to measure their symptoms that has a maximum score of 104. But for the 63 people on extended-release amantadine, the improvement was 15.9 points .... Reuters

6/14 Moving Beyond "Ask Your Doctor" — "Emotional Storytelling" is the New Direction for Pharma Ads
Healthcare brands turn to emotion, to better tell their stories .... Pharmaceutical companies are starting to use new tools like virtual reality and artificial intelligence as well as proven strategies like humor and storytelling as they seek to improve a customer experience long considered reactive and inauthentic .... MM&M

Stat's Adam Feuerstein Finds a Company Doing Disease Awareness for a Drug Still in Phase 3
6/14 Internet Drug News Fast Takes:
Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials
Prenatal fever linked to autism risk
South Africa Probes Roche, Aspen, Pfizer on Cancer-Drug Pricing
Biogen exodus continues as CFO set to join Alexion
Boston Business Journal
FBI is investigating an Oregon health care startup
Hand-washing is like hitting a reset button in the brain
McKesson CEO slashes price on Orinda home by $6 million after a year on the market
San Francisco Business Times

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 6/19/2017

If your intellectual property being infringe
e-mail the webmaster and we will fix it. 

The information on this site is not meant as medical advice.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

The information contained on this web site is for your information only.  Never take a drug without a doctor's prescription - only an idiot does that.   
Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

Do NOT start or stop taking a medicine based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!